These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 26785031)

  • 1. Diffused alveolar hemorrhage: A rare and severe complication of tirofiban-induced thrombocytopenia.
    Zhou X; Peng H; Yin Y; Huang H; Zeng J; Ouyang F
    Int J Cardiol; 2016 Mar; 206():93-4. PubMed ID: 26785031
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review.
    Elcioglu OC; Ozkok A; Akpınar TS; Tufan F; Sezer M; Umman S; Besısık SK
    Int J Hematol; 2012 Sep; 96(3):370-5. PubMed ID: 22767141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirofiban for myocardial infarction.
    Juwana YB; Suryapranata H; Ottervanger JP; van 't Hof AW
    Expert Opin Pharmacother; 2010 Apr; 11(5):861-6. PubMed ID: 20210689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vanishing platelets: rapid and extreme tirofiban-induced thrombocytopenia after percutaneous coronary intervention for acute myocardial infarction.
    Rahman N; Jafary FH
    Tex Heart Inst J; 2010; 37(1):109-12. PubMed ID: 20200641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of upstream administration of tirofiban before percutaneous coronary intervention on spontaneous reperfusion and clinical outcomes in acute ST-segment elevation myocardial infarction.
    Zhu J; Zhang T; Xie Q; Zhang J
    Angiology; 2015 Jan; 66(1):70-8. PubMed ID: 24327765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tirofiban-induced acute profound thrombocytopenia after primary angioplasty.
    Dursunoglu D; Taskoylu O; Gür S; Sari I
    Asian Cardiovasc Thorac Ann; 2013 Feb; 21(1):74-6. PubMed ID: 23430426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Severe tirofiban-induced thrombocytopenia and thrombotic microangiopathy after percutaneous coronary intervention].
    Nettersheim FS; Hohmann C; Pfister R; Michels G
    Dtsch Med Wochenschr; 2019 Jan; 144(2):109-113. PubMed ID: 30674059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
    Li W; Fu X; Xue H; Wang Y; Wang X; Zhao Y; Geng W; Yang Z; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
    Cardiovasc Ther; 2013 Aug; 31(4):210-4. PubMed ID: 22954393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety evaluation of tirofiban.
    Valgimigli M; Tebaldi M
    Expert Opin Drug Saf; 2010 Sep; 9(5):801-19. PubMed ID: 20670206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of 12 versus 24 hours of tirofiban infusion in patients undergoing primary percutaneous coronary intervention.
    Topcu S; Karal H; Kaya A; Bakirci EM; Tanboga IH; Kurt M; Aksakal E; Acikel M; Sevimli S
    Clin Appl Thromb Hemost; 2015 Nov; 21(8):783-9. PubMed ID: 24737688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report.
    Eryonucu B; Tuncer M; Erkoc R
    Cardiovasc Drugs Ther; 2004 Nov; 18(6):503-5. PubMed ID: 15770438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention.
    Tavano D; Visconti G; D'Andrea D; Focaccio A; Golia B; Librera M; Caccavale M; Ricciarelli B; Briguori C
    Am J Cardiol; 2009 Nov; 104(9):1222-8. PubMed ID: 19840566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Zhang Y; Gao C; Liu H; Wang X; Yang H; Li M; Wang X; Zhu Z; Hu D
    Clin Exp Pharmacol Physiol; 2013 Apr; 40(4):289-94. PubMed ID: 23551127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.
    Zhu TQ; Zhang Q; Qiu JP; Jin HG; Lu L; Shen J; Zhao LP; Zhang RY; Hu J; Yang ZK; Shen WF
    Int J Cardiol; 2013 May; 165(3):437-43. PubMed ID: 21940058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment.
    Mulot A; Moulin F; Fohlen-Walter A; Angioi M; Sghaier M; Carteaux JP; Lecompte T; de Maistre E
    Am J Hematol; 2004 Sep; 77(1):67-71. PubMed ID: 15307109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of tirofiban therapy in very old patients with acute coronary syndrome or non-Q-wave myocardial infarction.
    Graf C; Nkoulou R; Trombert V; Perrenoud JJ
    J Am Geriatr Soc; 2005 Jan; 53(1):172-3. PubMed ID: 15667404
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.